Health Care • Biotechnology: Pharmaceutical Preparations
$2.27 ▼ -0.39
(-14.66%)
MKT CAP: $115.2M • VOL: 15.64M
52W L $2 52W H $5
ROARABLE / RQD
D- • 36/100
PIOTROSKI
2 / 9
NRXP // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $1.2M | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | $720.0K | — | — |
| Gross Margin % | 58.8% | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$16.2M | -$18.5M | -$27.8M |
| Operating Margin % | -80.0% | — | — |
| Net Income (GAAP) | -$28.6M | -$25.1M | -$30.1M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$14.1M | -$10.6M | -$21.7M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$14.1M | -$10.6M | -$21.7M |
| FCF Margin % | -80.0% | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $7.8M | $1.4M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | -$15.9M | -$23.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR NRXP.